Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Esperion reported FY2025 total revenue of $403.1 million (+21% YoY), with US net product revenue of $159.6 million (+38% YoY) for Nexletol and Nexlizet.…
ARCHIMED-managed funds will acquire Esperion Therapeutics for up to $1.1 billion in equity value, paying $3.16 per share in cash at closing, a 58% premium to…
Esperion Therapeutics has agreed to a $1.1 billion take-private buyout by ARCHIMED-managed funds, with shareholders receiving $3.16 per share in cash plus…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
ARCHIMED-managed funds (via Essence Parent Inc. / Essence MergerCo Inc.) entered a definitive merger agreement on 5/1/26 to take Esperion (ESPR) private for $3.16/share in cash plus one non-tradeable CVR; total equity value up to ~$1.1B. The $3.16 upfront is a 58% premium to the 4/30/26 close. The CVR splits into two milestones: up to $40M tied to bempedoic acid (NEXLETOL/NEXLIZET) 2027 US net sales (full above $350M, linear from $300-350M), and up to $60M tied to ENBUMYST (bumetanide) if US net sales reach $160M in any calendar year through 12/31/2030. Financing (~$706M equity + $550M debt from Pharmakon Advisors / BioPharma Credit) is committed and not a closing condition; the agreement carries a $34.2M company termination fee and a $68.3M reverse termination fee. Closing is expected in Q3 2026 (outside date 11/1/26), subject to a shareholder vote and HSR + German merger control clearances. As of 6/7/26 the deal remains pending: a preliminary proxy (PREM14A) has been filed but the special-meeting date is not yet set, and no superior proposal has emerged.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| ARCHIMED (private equity) / Esperion Therapeutics Inc. (this deal) | 2026 | $1.1B | — |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Astra AB / Zeneca Group plc | 1998 | $35.0B | 94 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
← Browse all deals · How we score deals
More: 2026 deals · Cardiovascular deals